fda semaglutide obesity What's New in Treatment? FDA Approves First ORAL GLP-1

Conclusions Consistent with clinical trials, real-world tirzepatide treatment was associated with greater 6-month weight reduction and more frequent achievement of weight-reduction targets and improvements in select cardiometabolic parameters than semaglutide among adults with obesity without diabetes

Novo Nordisks semaglutide added another win to its books, this time showing significantreductionsin symptoms in patients with heart failure with preserved ejection fraction (HFpEF)

Compound:SEMA (GLP-1) Research Peptide

A GLP-1 derivative and fragment of dulaglutide

Compounded GLP-1 therapy for weight loss can put you on track to achieve your ideal figure

More than four in five PwO have made a serious attempt at weight loss but less than half of them would have lost 5% of their body weight over three years, and 70% of those that do are expected to regain their losses.11 This illustrates that regardless of the drivers of obesity, PwO are in an established state of pathological energy homeostasis that requires intensification of treatment beyond foundational lifestyle changes, and which often requires the use of anti-obesity medications (AOMs)